Non-small cell lung cancer
Conditions
Interventions
Index test:To verify whether CSNK2B and SLC52A2 gene expression levels can be used as biomarkers for the early diagnosis of NSCLC and to predict whether NSCLC patients will respond to PD-L1 immunother
Sponsors
First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Subjects aged 18-80 years who were newly diagnosed with NSCLC and healthy controls were recruited during the 3-year period from January 1, 2025 to January 1, 2028; 2.Subjects have been diagnosed with non-small cell lung cancer and plan to receive or have begun PD-L1 treatment; 3.The subject is willing to provide blood or tissue samples for research purposes; 4.Subjects have health conditions that allow them to receive anti-PD-L1 therapy and participate in regular follow-up; 5.Subjects have read the relevant information and agreed to participate in the study;
Exclusion criteria
Exclusion criteria: 1.The subject is under 18 years old or over 80 years old; 2.The subject has other serious health problems, such as active infections or other malignant tumors; 3.The subject is unwilling to provide the necessary biological samples; 4.Subjects have a history of allergy or other serious side effects of anti-PD-L1 treatment; 5.The subjects were unable to understand the research information or to give informed consent;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The occurrence of non-small cell lung cancer;Whether PD-L1 is effective in treating non-small cell lung cancer;Receiver operating characteristic curve (ROC Curve);The area under the AUC curve;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive predicative value;Negative predictive value; | — |
Countries
China
Contacts
Public ContactXIONG Qiuxia
First Affiliated Hospital of Kunming Medical University
Outcome results
None listed